Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease : Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial
Copyright © 2024 Elsevier Inc. All rights reserved..
BACKGROUND: Kawasaki disease is a pediatric acute systemic vasculitis that specifically involves the coronary arteries. Timely initiation of immunoglobulin plus aspirin is necessary for diminishing the incidence of coronary artery abnormalities (CAAs). The optimal dose of aspirin, however, remains controversial. The trial aims to evaluate if low-dose aspirin is noninferior to moderate-dose in reducing the risk of CAAs during the initial treatment of Kawasaki disease.
METHODS: This is a multi-center, prospective, randomized, open-label, blinded endpoint, noninferiority trial to be conducted in China. The planned study duration is from 2023 to 2026. Data will be analyzed according to intention-to-treat principles. Participants are children and adolescents under the age of 18 with Kawasaki disease, recruited from the inpatient units. A sample size of 1,346 participants will provide 80% power with a one-sided significance level of 0.025. Qualifying children will be randomized (1:1) to receive either intravenous immunoglobulin (2 g/kg) plus oral moderate-dose aspirin (30-50 mg·kg-1·d-1) until the patient is afebrile for at least 48 hours, or immunoglobulin plus low-dose aspirin (3-5 mg·kg-1·d-1) as initial treatment. The primary outcome will be the occurrence of CAAs at 8 weeks after immunoglobulin infusion. Independent blinded pediatric cardiologists will assess the primary endpoint using echocardiography.
CONCLUSIONS: There is a shortage of consensus on the dose of aspirin therapy for Kawasaki disease due to the lack of evidence. The results of our randomized trial will provide more concrete evidence for the efficacy and adverse events of low- or moderate-dose aspirin in the acute phase of Kawasaki disease.
TRIAL REGISTRATION: www.chictr.org.cn: ChiCTR2300072686.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:273 |
|---|---|
| Enthalten in: |
American heart journal - 273(2024) vom: 19. März, Seite 1-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Yujian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ahj.2024.03.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369981537 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369981537 | ||
| 003 | DE-627 | ||
| 005 | 20240421232037.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ahj.2024.03.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1382.xml |
| 035 | |a (DE-627)NLM369981537 | ||
| 035 | |a (NLM)38508571 | ||
| 035 | |a (PII)S0002-8703(24)00071-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Yujian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease |b Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Kawasaki disease is a pediatric acute systemic vasculitis that specifically involves the coronary arteries. Timely initiation of immunoglobulin plus aspirin is necessary for diminishing the incidence of coronary artery abnormalities (CAAs). The optimal dose of aspirin, however, remains controversial. The trial aims to evaluate if low-dose aspirin is noninferior to moderate-dose in reducing the risk of CAAs during the initial treatment of Kawasaki disease | ||
| 520 | |a METHODS: This is a multi-center, prospective, randomized, open-label, blinded endpoint, noninferiority trial to be conducted in China. The planned study duration is from 2023 to 2026. Data will be analyzed according to intention-to-treat principles. Participants are children and adolescents under the age of 18 with Kawasaki disease, recruited from the inpatient units. A sample size of 1,346 participants will provide 80% power with a one-sided significance level of 0.025. Qualifying children will be randomized (1:1) to receive either intravenous immunoglobulin (2 g/kg) plus oral moderate-dose aspirin (30-50 mg·kg-1·d-1) until the patient is afebrile for at least 48 hours, or immunoglobulin plus low-dose aspirin (3-5 mg·kg-1·d-1) as initial treatment. The primary outcome will be the occurrence of CAAs at 8 weeks after immunoglobulin infusion. Independent blinded pediatric cardiologists will assess the primary endpoint using echocardiography | ||
| 520 | |a CONCLUSIONS: There is a shortage of consensus on the dose of aspirin therapy for Kawasaki disease due to the lack of evidence. The results of our randomized trial will provide more concrete evidence for the efficacy and adverse events of low- or moderate-dose aspirin in the acute phase of Kawasaki disease | ||
| 520 | |a TRIAL REGISTRATION: www.chictr.org.cn: ChiCTR2300072686 | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Hu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Xiaofei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanfei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Fengxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jianbin |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Shuliang |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhouping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American heart journal |d 1945 |g 273(2024) vom: 19. März, Seite 1-9 |w (DE-627)NLM000012270 |x 1097-6744 |7 nnns |
| 773 | 1 | 8 | |g volume:273 |g year:2024 |g day:19 |g month:03 |g pages:1-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ahj.2024.03.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 273 |j 2024 |b 19 |c 03 |h 1-9 | ||